Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
about
Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypesWhen to start antiretroviral therapy: as soon as possibleHIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?The end of AIDS: HIV infection as a chronic diseaseImmunologic Biomarkers, Morbidity, and Mortality in Treated HIV InfectionDeep transcriptional sequencing of mucosal challenge compartment from rhesus macaques acutely infected with simian immunodeficiency virus implicates loss of cell adhesion preceding immune activationHIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammationHIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.Immune activation and HIV persistence: considerations for novel therapeutic interventions.Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy.Residual immune dysregulation syndrome in treated HIV infection.The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.Can early therapy reduce inflammation?Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyGut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHST cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection.Lack of evidence for mtDNA as a biomarker of innate immune activation in HIV infectionHypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study.Dissemination of research findings to research participants living with HIV in rural Uganda: challenges and rewardsInitiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationA randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.Persistent immune activation in chronic HIV infection: do any interventions work?Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection.Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.Activation associated ERK1/2 signaling impairments in CD8+ T cells co-localize with blunted polyclonal and HIV-1 specific effector functions in early untreated HIV-1 infection.HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation LevelsRisk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAARTGut epithelial barrier and systemic inflammation during chronic HIV infection.T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating Antiretroviral Therapy.Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIVMultidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV InfectionCirculating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control StudyEffects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.
P2860
Q21245213-BA405539-84DF-4200-9292-5C220F4F93FDQ27006767-179DB510-FD86-4517-B71E-033438652845Q27010874-5A6E4A35-935F-4165-8A96-C40ECCFA1CDFQ28300749-936766F3-E3A2-4E28-8C5B-5507BC7ABBA1Q30245379-7FC7FCD0-E537-4036-8DF0-18795B6E4954Q30362325-82CBE160-131C-4014-B51C-834C2420534AQ30839904-F248DB96-2F2C-42B1-AFC3-501321D0B5A8Q33618542-97CCB933-7903-4271-88AE-27B31B67D4E8Q33698781-B212F8B5-B437-4D4E-901B-D0A0DEB4793DQ33707759-EE876628-AFA1-42DD-AA0E-85EB4869562DQ33828349-D7BE814D-A315-4AE9-8419-FF6855AE1703Q34016057-84C56015-9264-4830-927D-72C7E105F699Q34020121-546A9514-3C14-4BAA-987C-5DEBE89DA7ECQ34106235-CB79FAF1-C74F-44FB-B496-8600FD7639E0Q34159822-0A40E28C-DD10-444B-BCB6-404F7D3C568FQ34206123-A3AB9E2F-B34C-4579-874E-1E73D52AF937Q34315572-0943FFD7-B30C-4734-96EF-9DAAADF195B3Q34315579-9DAC7C8E-0E54-4274-B723-1FC155BCE204Q34342183-E8A93654-B2B8-4C62-89AC-821747CF6E90Q34344703-0F35C659-AB44-4ECC-BEB8-1CCD18A5F77EQ34351320-9D891D9A-2A91-4AB5-957E-29CD72746E44Q34373981-0766BD56-BEE8-420C-8772-26F4B335D5A3Q34500351-3D86012A-55F9-4F04-8A4B-F1E3F186B4DFQ34568454-13D24882-3434-4EA0-8AA4-6B6B372BD29CQ34614224-43DF87AA-1946-44D1-A51F-C1E20351F8E8Q34682171-F35DB8CC-BE88-479A-8883-BA01A9295C2EQ34743336-B0AB2AE8-8A19-4454-9F0C-EC06270D717CQ34851102-EC961EC3-5202-4149-8FE9-2372DE22DB31Q34943158-148519FA-635C-4E6C-9243-FBC5F35D4024Q35018065-B6B233E0-8FD5-4667-BB8B-515A8DF23EF9Q35021753-5D7C752A-B0DD-46BB-9F8C-7C9A3BCB1AA9Q35588137-B6BC0628-5F8E-4957-9FBB-FA5E682A1542Q35645143-D20F27EC-A0D9-4071-8F6C-F886E74EC96DQ35648710-7574EE40-FE25-4C81-8940-18AFF6F7E4A3Q35666026-F8B642A9-1C5E-4098-8E72-42BB6235F0ADQ35711609-E5692B24-B34A-4DF9-9BE3-24F102E57CE6Q35766808-1F31A38D-2FF1-4823-876D-84AC2C0E4AEAQ35786633-1CBD993D-D3E1-4B2E-AF0C-AA341864FE63Q35806035-DC688D21-E1C3-49C3-B7E8-A63D91867706Q35904816-82B3F45D-9D09-45DA-90DC-1502FE3DF7AA
P2860
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@ast
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@en
type
label
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@ast
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@en
prefLabel
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@ast
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@en
P2093
P2860
P921
P1433
P1476
Impact of CD8+ T-cell activati ...... iating antiretroviral therapy.
@en
P2093
Annet Kembabazi
Conrad Muzoora
Huyen L Cao
Isaac Ssewanyana
Jeffrey N Martin
John Bennett
Nneka Emenyonu
Peter W Hunt
Torsten B Neilands
P2860
P304
P356
10.1097/QAD.0B013E32834C4AC1
P407
P577
2011-11-01T00:00:00Z